SCYNEXIS (LTS:0L49) Dividends Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0L49 SCYNEXIS Inc LTS:0L49
45 GF Score
Price $5.27
GF Value $17.91
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is SCYNEXIS Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

LTS:0L49
45GF Score
SCYNEXIS Inc LTS:0L49
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is SCYNEXIS (LTS:0L49) Overvalued in 2026?

Based on GuruFocus' analysis, SCYNEXIS stock appears to be undervalued. The current stock price of $5.27 is trading 70.6% below its estimated GF Value™ of $17.91. GuruFocus considers SCYNEXIS to be Possible Value Trap.

Key valuation signals for LTS:0L49:

  • Dividends Received:
  • GF Value™: $17.91 vs. price of $5.27 (70.6% below fair value)
  • GF Score™: 45/100 with 3 warning signs

No single metric tells the full story. See the LTS:0L49 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


SCYNEXIS Business Description

Other Exchanges SCYX:USA135:Germany
Address 1 Evertrust Plaza, 13th Floor, Jersey City, NJ, USA, 07302 - 6548
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
45GF Score

Get the complete analysis for LTS:0L49

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.27
Price
$17.91
GF Value